immunosuppression

PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade

By MedXY 11/07/2025

Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 blockade restores antitumour immunity in preclinical models, supporting biomarker‑driven combination trials.

Cardiology Pediatrics Specialties Transplantation

Everolimus and Low-Dose Tacrolimus Therapy After Pediatric Heart Transplant: Insights from a Multicenter Randomized Clinical Trial

By MedXY 10/21/2025

This randomized trial evaluates the safety and efficacy of everolimus combined with low-dose tacrolimus versus standard immunosuppression in children 6 months post-heart transplant, highlighting comparable rejection rates, improved kidney function, and reduced CMV infection risk.

Dermatology Nephrology news

Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program

By MedXY 10/15/2025

A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.

Clinical Updates General Surgery news Transplantation

Combined Liver–Kidney Transplantation: Four Decades of Transformative Impact and Future Horizons

By MedXY 09/25/2025

Since the landmark combined liver–kidney transplant in 1984, advances in surgical techniques, immunosuppression, and donor allocation have revolutionized care for patients with dual organ failure. Emerging innovations, including gene-edited xenotransplantation, promise further breakthroughs.

news Oncology Specialties

Immunosuppressive Roles of Tumour-Infiltrating B Cells in Intrahepatic Cholangiocarcinoma and Implications for Chemoimmunotherapy Outcomes

By MedXY 09/04/2025

This article reviews the immunosuppressive mechanisms of tumour-infiltrating B cells in intrahepatic cholangiocarcinoma (iCCA), their impact on prognosis, and potential to enhance chemoimmunotherapy efficacy by restoring B-cell function and promoting tertiary lymphoid structures.